P3232 - Prevalence and Factors Associated With Optimal Disease Control in Crohn’s Disease and Ulcerative Colitis: Views on Inflammatory Bowel Disease Expectations and Well-Being by Patients and Treatment Providers

Marla C. Dubinsky, MD¹, Simon Travis, ², Alison Potts Bleakman, ³, Gabriella McCarty, DNP, MSN, NP-C⁴, Nour Altimimi, ⁵, Latonia Ward, ⁶, Eric Kamer, ³, Sarah Folian, ³, Charles Owen, ⁷, Xian Zhou, ³, Vanda Palace, ⁸, Giorgio Castellano, ⁸, Remo Panaccione, MD⁹
1Susan and Leonard Feinstein IBD Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York, NY; 2Translational Gastroenterology Unit, University of Oxford and Oxford Biomedical Research Centre, Oxford, UK, Oxford, England, United Kingdom; 3Eli Lilly and Company, Indianapolis, IN; 4North Shore Gastroenterology, Westlake, OH; 5South Asian IBD Alliance (SAIA), East Dundee, IL; 6Color of Gastrointestinal Illnesses (COGI), Maryland, MD; 7Former employee of Eli Lilly and Company, Indianapolis, IN; 8Adelphi Real World, Bollington, England, United Kingdom; 9Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, AB, Canada, Calgary, AB, Canada

Introduction: Views on Inflammatory Bowel Disease (IBD) Expectations and Well-being - Patients and Treatment providers (VIEW-PT): an analysis based on the IBD Disease Specific Programme (DSP)™, previously identified features of optimal disease control (ODC). This study assessed prevalence of ODC and associated factors in a real-world setting.

Methods: Data were from the IBD DSP, a cross-sectional survey of healthcare professionals (HCPs) and their patients (pts) with IBD, in EU5 (France, Germany, Italy, Spain, the United Kingdom), and the United States, collected 2020-21 and 2023-24. Pts with history of moderate-to-severe IBD (Crohn’s disease or ulcerative colitis) were included in this study. HCPs reported pt demographics, clinical characteristics, treatment history, healthcare resource utilization and treatment targets set/achieved. Pts self-reported symptoms, involvement in treatment decision and health-related quality of life via Visual Analogue Scale (EQ-VAS). Pts with no key symptoms (bleeding, bowel urgency, fecal incontinence, abdominal pain, fatigue), with restored bowel movement frequency, extraintestinal manifestations control, complete mucosal healing, no steroid use, no sleep disturbance, and EQ-VAS ≥80 met criteria for ODC. Logistic regression was performed to determine association of factors with ODC.

Results: Of 2614 pts with IBD, 10.0% had ODC aligned with features identified in VIEW-PT. Table 1a shows pt demographics. Logistic regression analysis included 1833 pts with complete data (Table 1b). Pts involved in treatment decisions (Odds ratio, OR=4.82, p< 0.001) and who achieved set treatment targets (OR=2.17, p=0.002) had higher odds of achieving ODC, while pts who had not achieved set treatment targets (OR=0.32, p=0.002) had lower odds of achieving ODC. Other factors associated with ODC included a previous history of smoking (OR=2.13, p=0.004) or having never smoked (OR=1.91, p=0.013), having a psychological comorbidity (OR=0.27, p=0.002), not receiving advanced therapy (OR=0.54, p=0.005), and having >4 HCP visits in the past 12 months (OR=0.42, p< 0.001).

Discussion: Pt involvement in treatment decisions and achievement of treatment targets were most strongly associated with ODC in IBD. Other significantly associated factors included no psychological comorbidities, none/ex-smoking status, and advanced therapy prescription. Involving patients in treatment decisions and setting and reaching targets may support achievement of ODC.


Figure: Demographics of patients with IBD (Crohn’s disease or ulcerative colitis) categorized by optimal disease control status (a) and factors associated with optimal disease control (b) globally (USA and EU5).

Disclosures:
Marla Dubinsky: AbbVie – Consultant, Grant/Research Support. Arena – Consultant. Astra Zeneca – Consultant. Boehringer Ingelheim – Consultant. Celgene – Consultant. Eli Lilly – Consultant. Gilead – Consultant. Janssen – Consultant, Grant/Research Support. Merck – Consultant. Pfizer – Consultant. Prometheus Laboratories – Consultant, Grant/Research Support. Sanofi – Consultant. Spyre – Consultant. Takeda – Consultant. Trellus Health – Stock Options, Stock-publicly held company(excluding mutual/index funds). UCB – Consultant.
Simon Travis: AbbVie – Grant/Research Support, Honoraria, Travel expenses. Alimentiv – Independent Contractor. Bioclinica – Consultant. Bristol Myers Squibb – Consultant. Cosmo – Consultant. Dova Health Intelligence – Consultant, Stock Options. ECCO Health Care – Grant/Research Support. Eli Lilly and Company – Consultant, Grant/Research Support, Honoraria. Equillium – Consultant. Ferring – Consultant, Honoraria, Travel expenses. Genentech – Consultant. GlaxoSmithKline – Consultant. Immunocore – Consultant. Immunometabolism – Consultant. Janssen – Consultant. Mestag – Consultant. MSD – Consultant. Norman Collisson Foundation – Grant/Research Support. Novartis – Consultant. Pfizer – Consultant, Grant/Research Support, Travel expenses. Protagonist – Consultant. Roche – Consultant. Satisfai – Consultant. Sorriso – Consultant. Spyre – Consultant. Takeda – Consultant, Honoraria, Travel expenses. The Helmsley Trust – Grant/Research Support. the International Organization for the Study of Inflammatory Bowel Diseases – Grant/Research Support. UCB – Consultant, Grant/Research Support. UK–India Education and Research Initiative – Grant/Research Support. Vifor – Consultant, Grant/Research Support.
Alison Potts Bleakman: Eli Lilly and Company – Employee, Stock Options.
Gabriella McCarty: Eli Lilly and Company – Speakers Bureau.
Nour Altimimi indicated no relevant financial relationships.
Latonia Ward indicated no relevant financial relationships.
Eric Kamer: Eli Lilly and Company – Employee, Stock Options.
Sarah Folian: Eli Lilly and Company – Employee, Stock Options.
Charles Owen: Eli Lilly and Company – Former employee of Eli Lilly and Company.
Xian Zhou: Eli Lilly and Company – Employee, Stock Options.
Vanda Palace: Adelphi Real World – Employee.
Giorgio Castellano: Adelphi Real World – Employee.
Remo Panaccione: Abbott – Consultant. AbbVie – Advisory Committee/Board Member, Consultant, Speaker's fees. Abivax – Consultant. Alimentiv – Advisory Committee/Board Member, Consultant. Amgen – Advisory Committee/Board Member, Consultant, Speaker's fees. AnaptysBio – Consultant. Arena Pharmaceuticals – Advisory Committee/Board Member, Consultant, Speaker's fees. AstraZeneca – Advisory Committee/Board Member, Consultant. Biogen – Advisory Committee/Board Member, Consultant. Boehringer Ingelheim – Advisory Committee/Board Member, Consultant. Bristol Myers Squibb – Advisory Committee/Board Member, Consultant, Speaker's fees. Celgene – Advisory Committee/Board Member, Consultant, Speaker's fees. Celltrion – Consultant. Cosmos Pharmaceuticals – Consultant. Eisai – Consultant. Elan Pharmaceuticals – Consultant. Eli Lilly and Company – Advisory Committee/Board Member, Consultant, Speaker's fees. Ferring Pharmaceuticals – Advisory Committee/Board Member, Consultant, Speaker's fees. Fresenius Kabi – Advisory Committee/Board Member, Consultant, Speaker's fees. Galapagos – Consultant. Genentech (Roche) – Advisory Committee/Board Member, Consultant. Gilead Sciences – Advisory Committee/Board Member, Consultant, Speaker's fees. GlaxoSmithKline – Advisory Committee/Board Member, Consultant. JAMP Pharma – Advisory Committee/Board Member, Consultant. Johnson & Johnson – Advisory Committee/Board Member, Consultant, Speaker's fees. Merck & Co., Inc. – Advisory Committee/Board Member, Consultant, Speaker's fees. Mirador – Consultant. Mylan – Advisory Committee/Board Member, Consultant. Novartis – Advisory Committee/Board Member, Consultant. Odyssey – Consultant. Oppilan Pharma – Advisory Committee/Board Member, Consultant. Organon – Advisory Committee/Board Member, Consultant, Speaker's fees. Pandion Therapeutics – Advisory Committee/Board Member, Consultant. Pendopharm G.I. Solutions – Consultant. Pfizer – Advisory Committee/Board Member, Consultant, Speaker's fees. Progenity – Advisory Committee/Board Member, Consultant. Prometheus Biosciences – Consultant. Protagonist Therapeutics Inc – Advisory Committee/Board Member, Consultant. Roche – Advisory Committee/Board Member, Consultant, Speaker's fees. Sandoz – Advisory Committee/Board Member, Consultant, Speaker's fees. Sanofi – Consultant. Satisfai Health – Consultant. Shire Pharma – Advisory Committee/Board Member, Consultant, Speaker's fees. Spyre Therapeutics – Consultant. Sublimity Therapeutics – Advisory Committee/Board Member, Consultant. Takeda Pharmaceuticals – Advisory Committee/Board Member, Consultant, Speaker's fees. Teva – Consultant. Theravance Biopharma – Consultant. Tillots – Consultant. Trellus Health – Consultant. UCB – Consultant. Union Biopharma – Consultant. Ventyx Biosciences – Advisory Committee/Board Member, Consultant. Viatris – Consultant.

Marla C. Dubinsky, MD¹, Simon Travis, ², Alison Potts Bleakman, ³, Gabriella McCarty, DNP, MSN, NP-C⁴, Nour Altimimi, ⁵, Latonia Ward, ⁶, Eric Kamer, ³, Sarah Folian, ³, Charles Owen, ⁷, Xian Zhou, ³, Vanda Palace, ⁸, Giorgio Castellano, ⁸, Remo Panaccione, MD⁹. P3232 - Prevalence and Factors Associated With Optimal Disease Control in Crohn’s Disease and Ulcerative Colitis: Views on Inflammatory Bowel Disease Expectations and Well-Being by Patients and Treatment Providers, ACG 2025 Annual Scientific Meeting Abstracts. Phoenix, AZ: American College of Gastroenterology.